Jefferies lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $12 from $14 and keeps a Buy rating on the shares while taking over lead coverage of the stock. FHD-909, Foghorn’s lead clinical asset partnered with Eli Lilly (LLY), has topline Phase 1 dose-escalation data along with a go/no-go decision on dose-expansion expected mid-2026 and the firm could see a 80% higher or 40% lower move on that data, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Jefferies Initiates Buy on Foghorn Therapeutics Driven by FHD‑909 Mid‑2026 Catalyst and Upside from Emerging EP300/CBP Degrader Pipeline
- Foghorn Therapeutics Announces $50 Million Equity Financing
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/18/2025, According to Top Analysts
- Foghorn Therapeutics initiated with a Buy at BTIG